Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Parand Daro Pharmaceutical Company is a prominent Iranian pharmaceutical manufacturer specializing in the production of narcotic and non-narcotic active pharmaceutical ingredients (APIs) and finished dosage forms. Established in 2004 and headquartered in the Parand Industrial City, the company focuses on the extraction and synthesis of opioid-based medications for pain management and addiction treatment. Its state-of-the-art facilities are GMP-certified, supporting the production of pellets, tablets, and capsules for both domestic and international markets. The company's extensive portfolio includes essential medicines such as codeine phosphate, morphine sulfate, methadone, and buprenorphine. Parand Daro plays a vital role in the regional healthcare infrastructure by providing controlled substances and palliative care solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Parand Daro.